-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JsFV3DofnnmmRZcsPqpnJwgF/HecFzbl1EDI8uN9cljKPuPqJWDgHFcJTdJWSnQG
 URXUsIUjO6x+l/1P1kgl3w==

<SEC-DOCUMENT>0001167379-02-000065.txt : 20021218
<SEC-HEADER>0001167379-02-000065.hdr.sgml : 20021218
<ACCEPTANCE-DATETIME>20021218110041
ACCESSION NUMBER:		0001167379-02-000065
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20021218
FILED AS OF DATE:		20021218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALCON INC
		CENTRAL INDEX KEY:			0001167379
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980205094
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31269
		FILM NUMBER:		02861151

	BUSINESS ADDRESS:	
		STREET 1:		6201 SOUTH FREEWAY
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76134
		BUSINESS PHONE:		8175516878

	MAIL ADDRESS:	
		STREET 1:		BOSCH 69 6331 HUNENBERG
		CITY:			SWITZERLAND
		STATE:			V8
		ZIP:			0000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>acl6kmox1.htm
<DESCRIPTION>OFFICIAL HTML FILING
<TEXT>
<HTML>
<HEAD>
<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>SECURITIES AND EXCHANGE COMMISSION</TITLE>
<META NAME="keywords" CONTENT="Form 6-K -- August Report.doc">
</HEAD>
<BODY>

<B><FONT SIZE=5>
<P>&nbsp;</P>
<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</P>
</B></FONT><P ALIGN="CENTER">Washington, D.C. 20549</P>
<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=4><P ALIGN="CENTER">FORM 6-K</P>
</B></FONT><FONT SIZE=3><P ALIGN="CENTER"></P>
</FONT><B><P ALIGN="CENTER">Report Of Foreign Issuer</P>
<P ALIGN="CENTER">Pursuant To Rule 13a-16 Or 15d-16 of</P>
<P ALIGN="CENTER">the Securities Exchange Act of 1934</P>
</B><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><P ALIGN="CENTER">For the month of December 2002</P>
<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=5><P ALIGN="CENTER">ALCON, INC.</P>
</B></FONT><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">B</FONT><FONT FACE="Tahoma" SIZE=3>&ouml;</FONT><FONT SIZE=3>sch 69<BR>
P.O. Box 62<BR>
6331 H&uuml;nenberg, Switzerland<BR>
011-41-41-785-8888<BR>
(Address of principal executive offices)<BR>
</P>
<P>[Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.]</P>
<P ALIGN="CENTER"></P></FONT>
<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=516>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">Form 20-F</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">x</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">Form 40 F</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="JUSTIFY">[Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.]</P>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P></FONT>
<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=516>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">Yes</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">No</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">x</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><FONT SIZE=2><P>&nbsp;</P>
<P>&nbsp;</P>
</FONT><U><FONT SIZE=3><P>&nbsp;</P>
</U><P>&nbsp;</P>
<P>Incorporation by Reference</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">This Report of Foreign Issuer on Form 6-K shall be incorporated by reference into the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 24, 2002 and the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on October 25, 2002.</P>

</FONT><FONT SIZE=2><P>&nbsp;</P>
</FONT><FONT SIZE=3><P>Alcon, Inc. issued the following News Release on December 17, 2002.</P>
<B><P ALIGN="CENTER"></P>
</FONT><P ALIGN="CENTER">&nbsp;</P>
</B><P ALIGN="RIGHT">Alcon, Inc.</P>
<P ALIGN="RIGHT">B&ouml;sch 69</P>
<P ALIGN="RIGHT">P.O. Box 62</P>
<P ALIGN="RIGHT">6331 H&uuml;nenberg, Switzerland</P>
<P ALIGN="RIGHT"></P>
<B><I><P ALIGN="JUSTIFY">For immediate release</P>
</B></I>
<B><P>Alcon's Moxifloxacin NDA</P>
<P>Accepted for FDA Review</P>
<DIR>

<P>H&uuml;nenberg, Switzerland - December 17, 2002 - </B>Alcon, Inc. (NYSE: ACL) has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for the ophthalmic use of moxifloxacin 0.5% ophthalmic solution. Moxifloxacin is a potent fourth-generation fluoroquinolone antibiotic that the company believes will be a major advance in the topical treatment and prevention of ocular infections. Alcon is now awaiting FDA approval of the NDA.</P>
<P>Alcon's NDA seeks approval for the use of this drug to treat bacterial conjunctivitis and ophthalmia neonatorum, with the latter receiving priority review status. Ophthalmia neonatorum is a bacterial ocular infection in newborns (from birth to one month). Alcon has studied moxifloxacin extensively in three major clinical trials, three human pharmacokinetic studies and several toxicology studies. </P>
<P>Moxifloxacin is highly soluble, which allows it to be dosed at a higher concentration than other topical ocular anti-microbial products marketed today. This makes it very effective against many types of harmful bacteria. </P>
<P>Moxifloxacin shows enhanced coverage against difficult-to-treat gram-positive bacteria, a class including Staphylococcus and Streptococcus, which account for an estimated 80% of eye infections. It is also highly active against Pseudomonas and bacteria resistant to currently-used quinolones, as well as against emerging bacterial threats, such as Mycobacterium and Chlamydia.</P>
<P>In addition to its efficacy benefits, it has a near neutral pH, resulting in little or no stinging when applied in the eye, an especially important consideration for newborns. Capping off its profile, moxifloxacin<B><I> </B></I>penetrates ocular tissue very well, allowing it to kill bacteria that infect the surface of the eye as well as infections that may occur within it.</P>
<P>Alcon, Inc. is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for more than 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.</P>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER"># # #</P>
<B><I><FONT FACE="Arial" SIZE=2>
</FONT><P>Caution Concerning Forward-Looking Statements. </B>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause future results to differ include, but are not limited to, the following: the possibility that moxifloxacin will not be approved by the FDA or such approval will be delayed, the outcome of future clinical trials, approval of competitiv
e drug applications by the FDA prior to approval of moxifloxacin, competition from other drugs already on the market or competitive drugs that reach the market in the future, challenges inherent in new product manufacturing and marketing, developments in legal cases and government regulation and legislation. You should read this press<FONT FACE="Arial"> </FONT>release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.</P>
</I>
<FONT FACE="Arial"><P>&nbsp;</P>
<P>&nbsp;</P></DIR>

</FONT><I><P ALIGN="RIGHT">For information, contact:</P>
</I><P ALIGN="RIGHT">Doug MacHatton (Alcon Investor Relations)</P>
<P ALIGN="RIGHT">800-400-8599</P>
<P ALIGN="RIGHT">Mary Dulle (Alcon Public Relations)</P>
<P ALIGN="RIGHT">817-551-8058</P>
<I><P ALIGN="RIGHT">www.alconinc.com</P>
</I><FONT FACE="Arial">
</FONT><FONT SIZE=2><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<B><P ALIGN="CENTER">SIGNATURES</P>
</B><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=619>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<B><FONT SIZE=2><P>Alcon, Inc.</B></FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>(Registrant)</FONT></TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">Date</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=2><P>December 18,  2002</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">By</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>/s/ Martin Schneider</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Name:  Martin Schneider</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Title:  Attorney in Fact</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">Date</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=2><P>December  18, 2002</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">By</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>/s/ Stefan Basler</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Name:  Stefan Basler</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="49%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Title:  Attorney in Fact</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<FONT SIZE=2>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P></FONT></BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>3
<FILENAME>acl6kmox1.pdf
<DESCRIPTION>PRINTER FRIENDLY PDF FILE
<TEXT>
<PDF>
begin 644 acl6kmox1.pdf
M)5!$1BTQ+C(-)>+CS],-"C(P(#`@;V)J#3P\(`TO3&EN96%R:7IE9"`Q(`TO
M3R`R,B`-+T@@6R`W.#0@,C0T(%T@#2],(#$T.38T(`TO12`U.#4X(`TO3B`T
M(`TO5"`Q-#0T-B`-/CX@#65N9&]B:@T@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!X<F5F#3(P
M(#$U(`TP,#`P,#`P,#$V(#`P,#`P(&X-"C`P,#`P,#`V-#<@,#`P,#`@;@T*
M,#`P,#`P,3`R."`P,#`P,"!N#0HP,#`P,#`Q,3@R(#`P,#`P(&X-"C`P,#`P
M,#$S-#$@,#`P,#`@;@T*,#`P,#`P,34R."`P,#`P,"!N#0HP,#`P,#`R,C<S
M(#`P,#`P(&X-"C`P,#`P,#(T-C<@,#`P,#`@;@T*,#`P,#`P,S(S."`P,#`P
M,"!N#0HP,#`P,#`S-#$X(#`P,#`P(&X-"C`P,#`P,#4R-S(@,#`P,#`@;@T*
M,#`P,#`P-30U,R`P,#`P,"!N#0HP,#`P,#`U-C(Y(#`P,#`P(&X-"C`P,#`P
M,#`W.#0@,#`P,#`@;@T*,#`P,#`P,3`P-R`P,#`P,"!N#0IT<F%I;&5R#3P\
M#2]3:7IE(#,U#2]);F9O(#$X(#`@4B`-+U)O;W0@,C$@,"!2(`TO4')E=B`Q
M-#0S-B`-+TE$6SPS9&,W,&(Q93(R-C,Q9C$Q86$X,V(U,C<Q-C=C.3<X,SX\
M,V1C-S!B,64R,C8S,68Q,6%A.#-B-3(W,38W8SDW.#,^70T^/@US=&%R='AR
M968-,`TE)45/1@T@("`@(`TR,2`P(&]B:@T\/"`-+U1Y<&4@+T-A=&%L;V<@
M#2]086=E<R`Q.2`P(%(@#2]/=71L:6YE<R`Q-B`P(%(@#2]/<&5N06-T:6]N
M(%L@,C(@,"!2("]865H@;G5L;"!N=6QL(&YU;&P@72`-+U!A9V5-;V1E("]5
M<V5.;VYE(`T^/B`-96YD;V)J#3,S(#`@;V)J#3P\("]3(#@X("]/(#$S.2`O
M1FEL=&5R("]&;&%T941E8V]D92`O3&5N9W1H(#,T(#`@4B`^/B`-<W1R96%M
M#0I(B6)@8&`&(@$&%@8&EOT,/`P(P`,48P5BC@:&&QU[M!(8NMK`XHINRKIG
MJGJ^.2[2:G.46,7`P"@!%&7+8&!QRV!@X("H!0(N!@:];T":&X@%P3K]&+@Y
M&UW,5FYXL=;9[`//PPX&4:9?DLT/RG@/0*P48&`PC0723$`\%R#``)'G',$-
M96YD<W1R96%M#65N9&]B:@TS-"`P(&]B:@TQ,S(@#65N9&]B:@TR,B`P(&]B
M:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@,3D@,"!2(`TO4F5S;W5R8V5S
M(#(S(#`@4B`-+T-O;G1E;G1S(#(Y(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@
M#3X^(`UE;F1O8FH-,C,@,"!O8FH-/#P@#2]0<F]C4V5T(%L@+U!$1B`O5&5X
M="!=(`TO1F]N="`\/"`O5%0R(#(U(#`@4B`O5%0T(#(W(#`@4B`O5%0V(#,Q
M(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,Q(#,R(#`@4B`^/B`-+T-O;&]R
M4W!A8V4@/#P@+T-S-2`R."`P(%(@/CX@#3X^(`UE;F1O8FH-,C0@,"!O8FH-
M/#P@#2]4>7!E("]&;VYT1&5S8W)I<'1O<B`-+T%S8V5N="`X.3$@#2]#87!(
M96EG:'0@,"`-+T1E<V-E;G0@+3(Q-B`-+T9L86=S(#,T(`TO1F]N=$)";W@@
M6R`M,38W("TS,#<@,3`P.2`Q,#`W(%T@#2]&;VYT3F%M92`O5&EM97-.97=2
M;VUA;B`-+TET86QI8T%N9VQE(#`@#2]3=&5M5B`P(`T^/B`-96YD;V)J#3(U
M(#`@;V)J#3P\(`TO5'EP92`O1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E(`TO
M1FER<W1#:&%R(#,R(`TO3&%S=$-H87(@,C4R(`TO5VED=&AS(%L@,C4P(#`@
M,"`P(#`@,"`P(#(W."`P(#`@,"`P(#(U,"`S,S,@,C4P(#`@-3`P(#4P,"`U
M,#`@-3`P(#4P,"`U,#`@#34P,"`U,#`@,"`U,#`@,"`P(#`@,"`P(#`@,"`W
M,C(@,"`W,C(@-S(R(#8V-R`V,3$@-S<X(#<W."`S.#D@,"`--S<X(#8V-R`Y
M-#0@-S(R(#<W."`V,3$@,"`W,C(@-34V(#8V-R`W,C(@,"`P(#<R,B`P(#`@
M,"`P(#`@,"`P(`TP(#4P,"`U-38@-#0T(#4U-B`T-#0@,S,S(#4P,"`U-38@
M,C<X(#`@,"`R-S@@.#,S(#4U-B`U,#`@-34V(#`@#30T-"`S.#D@,S,S(#4U
M-B`U,#`@-S(R(#4P,"`P(#0T-"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(`TP(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M#3`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@-34V(%T@#2]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG
M(`TO0F%S949O;G0@+U1I;65S3F5W4F]M86XL0F]L9"`-+T9O;G1$97-C<FEP
M=&]R(#(V(#`@4B`-/CX@#65N9&]B:@TR-B`P(&]B:@T\/"`-+U1Y<&4@+T9O
M;G1$97-C<FEP=&]R(`TO07-C96YT(#@Y,2`-+T-A<$AE:6=H="`P(`TO1&5S
M8V5N="`M,C$V(`TO1FQA9W,@,S0@#2]&;VYT0D)O>"!;("TQ.#0@+3,P-R`Q
M,#@Y(#$P,C8@72`-+T9O;G1.86UE("]4:6UE<TYE=U)O;6%N+$)O;&0@#2])
M=&%L:6-!;F=L92`P(`TO4W1E;58@,3,S(`T^/B`-96YD;V)J#3(W(#`@;V)J
M#3P\(`TO5'EP92`O1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E(`TO1FER<W1#
M:&%R(#,R(`TO3&%S=$-H87(@,C4R(`TO5VED=&AS(%L@,C4P(#`@,"`U,#`@
M,"`X,S,@,"`Q.#`@,S,S(#,S,R`P(#`@,C4P(#,S,R`R-3`@,C<X(#4P,"`U
M,#`@-3`P(#4P,"`--3`P(#4P,"`U,#`@-3`P(#4P,"`U,#`@,C<X(#`@,"`P
M(#`@,"`P(#<R,B`V-C<@-C8W(#<R,B`V,3$@-34V(`TP(#<R,B`S,S,@,"`W
M,C(@-C$Q(#@X.2`W,C(@-S(R(#4U-B`P(#8V-R`U-38@-C$Q(#<R,B`P(#DT
M-"`P(#<R,B`-,"`S,S,@,"`S,S,@,"`P(#`@-#0T(#4P,"`T-#0@-3`P(#0T
M-"`S,S,@-3`P(#4P,"`R-S@@,C<X(#4P,"`R-S@@#3<W."`U,#`@-3`P(#4P
M,"`U,#`@,S,S(#,X.2`R-S@@-3`P(#4P,"`W,C(@-3`P(#4P,"`T-#0@,"`P
M(#`@,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(`TP(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M#3`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#4P,"`P(#`@,"`P(#`@-3`P(`U=(`TO
M16YC;V1I;F<@+U=I;D%N<VE%;F-O9&EN9R`-+T)A<V5&;VYT("]4:6UE<TYE
M=U)O;6%N(`TO1F]N=$1E<V-R:7!T;W(@,C0@,"!2(`T^/B`-96YD;V)J#3(X
M(#`@;V)J#5L@#2]#86Q21T(@/#P@+U=H:71E4&]I;G0@6R`P+CDU,#4@,2`Q
M+C`X.2!=("]'86UM82!;(#(N,C(R,C$@,BXR,C(R,2`R+C(R,C(Q(%T@#2]-
M871R:7@@6R`P+C0Q,C0@,"XR,3(V(#`N,#$Y,R`P+C,U-S8@,"XW,34Q.2`P
M+C$Q.3(@,"XQ.#`U(#`N,#<R,B`P+CDU,#4@72`^/B`-#5T-96YD;V)J#3(Y
M(#`@;V)J#3P\("],96YG=&@@,3<W.2`O1FEL=&5R("]&;&%T941E8V]D92`^
M/B`-<W1R96%M#0I(B8Q76W/C-!1^SZ\XC]),[;5D6[8?NVD+!;9EVC#`L#RD
MCI,8$KMC.]N%'\X3#YR+;*>%G:';6<G2N5^^H[Y?+=ZM5A8,K+8+DT.$_W`Q
MQH86G#-A86%U7+Q;]BF4/5]'T)>+=U\]&MCUBR`*H\C$L"H7M$L<K%X6OZC'
MZ^4/#SI(PUS=KFZO=9"%3CW"Y=T57/^D`Y2>JN77EW=?7</R_L.'V\?'V_L[
M_>OJ&[(F\=98L<:"35R(BTNRT#@RAU1%EI0&XY:T_J@#I]8Z4?V^;G;:1*%5
M@PZL:IL+N`J7(=@H38I1S^AU$D:)J.*=S4R8.G`16I^3-M9A\]''*!-M-_</
M'\"1:T8%.HAQ^99%GQMN,(QI5DQBHBE4M",Q#]5SVPUPOR5)L8(;LCM5+48I
MPN^NJG<-W/;]J>I8>F##'`(3FA165XN(Q8FD[XDS5R>R)5==?UHW`ZQ:>#@=
M*C#Q.L#@W7=@T@WMVBV+0UW9+$YL=).-/IW#OH+'JCQU]5!7/5Q_+O?K9E?!
M98D11UT#2>,<@RGBY$TBH[!(`6VRR:3"V%&%\;F[:3L@-<>V&?8H#JYT4*BJ
MK(Y/&`D,HZJT104=YC"R;U.8AH63H//.IBY,$DA<$<9V*IAD*ACK8W_YW?+^
M[@)N[\2-9?BV!,U4&KRS>0I)8JD\2.@4>_5>KWXC/C=Z[%R,7.BN^LM?3<%(
MDSB5N[&:QC+FPE)]N0=7$!>F)<N,3X^U<_2FX#'#]^%]"._;S^`L<\5ARBP)
M]>758DYI<)Y3%\<&OOZ[J9HGC=ZEJNIVLKG0$67R\:4>_M1%F&'DZ?^.ZBI6
MAW4C9!LI]C!'V\Y-/"_)R)A`FPQCFQ@NZ$*-WSI2;XZR/'U]D../U'P\!^+,
M*S-GE+:D\*.ZW&RZ2GJH[Z'5B#6QPNHDR('G3N?X63>E4-3D4Z*>U_)Y`,_Y
M61L\QHH?=#:3?1)AE4:5B7HEV^'"DH6R'"WXJ,4!C)@CRY'4%G$Z>5#,'A3B
MP2^WVE"XFTU=KH<*-$?DZ0]2EBLH]U7YN]\?M<GQ;HWY,JH;3U_V%382=9,<
M5$!.X\ID.SFLR>A"]8-&I*",TN$@A[!E^OJ`3AB%,11^>*D/2'WP1&+7MJ:C
M"D81S6E-3`?HF/G9\PX]G#S!IO+BRO:3-U#LAYM6OKNC(-.KHGK=P)%/MXT"
MBH%5-V@E"D!6K!S,31)Q*:5JO$?PL"K\E247U"#XG5LWR<YGV?F$2$>I0X0<
MEF9$FD-I@8T<9?TSHA0B'LMW:N9((@1RTG6]6ABH86%Q>%F(;4H3-8D(GJB*
M<@S48KM(8JJ/LVN$K;/K]ZM_05$101Q9/Z$8TSRD&G1KJB0;S75D$4VXCFA2
MC77$^R-5G.4Z2KB.^/1%9VK/89OKB2ZHG@I:F7PGA[4T`=43#2TJ!SH>Y!@F
MM=M3YZ_J?O^*M?&2>`K()*N;+6MJV8IN-'.H6R%ML(9>*Z+BDRYDD=5FDN0W
MP[YF"_O_+C$[0FN1CE->QUCF9('Q%J")=0]K[`4TIF\E+HB>&L<5^SEYZ7T4
M<S+Q\%_^O9%-WC$O>"P<6N&0KZ5V/B!&>0Z_>"5]C_PC]?.)).%+@!9*;ZSP
M28`2_?V#=HKO#I,"8]G*.""IA;(?U9/'L.A_P.^)VMM#`S\:-+ZI#`&I8&57
M,YX.LLA30I!RSXB[;G:O,?:R'+PX?!*80B[CQ#<RO5)M'M/C(HFQ6<8!F>1G
M,^CGBJ8[UB9ZB*\_BM\=#I^6>CB+L(-]FTJ'VMA14WVI0^?K_].A!NGF%ZLQ
M<[R,V'8K"(X)1ZO*MD.\7-/(L8JRR*"OX*%"0):(X!2N"&E5*5_5F)G7:.:A
M(*9!0VI6%`'J9D/0C=6+CT[98R4IPN-".@B1"^-\0UG+Y(Y@G*IK)_3X%*7"
MR!4_2`&-%)@L?+WFR@5"\*T.*/7C<;_GCJ'1X$^>*L`YW(I<]-QO\)9G&JOU
M1E$?>Z8_A&S\'NW;^A7#4\JN&DGJ1EBDD?Z[[TWF^]Y#YX-.L6(XY'YD.AGM
M.`^';NVQ1&<R2>FX'1&&2SXARV-N9R:J>%1COIK!DTWT$C^Z'`5P`%.5PQ9'
M\`9QV/$3)&/XFG#,-Q>_4BB#;B2I*R%!C&HV8CJ_V&7K.VQR#I;L*D8?+3BR
M!&].+5""OY=LP;/P=:+F\`5,&*>0,WZ,VN3"VTP/=S^&T#*8@QAS]ULUXN)#
MQ38:B2UU;B$%2A\=5]&:K'>>VY.AI8\T#2;2M5Q+\"T'GPM6A'?^&)GP3Q=^
M=!9ST&MF?1MO$N[!S$@DXC'@,0=<;C93P,T8<*.^4'I1.K\\?+LNVZ,FQ.+'
M1'J6B/L2(X%>MT\5;_"/H?0"+!5\HC"ZX8AE_PP`JOJD@PIE;F1S=')E86T-
M96YD;V)J#3,P(#`@;V)J#3P\(`TO5'EP92`O1F]N=$1E<V-R:7!T;W(@#2]!
M<V-E;G0@,3`P,"`-+T-A<$AE:6=H="`P(`TO1&5S8V5N="`M,C`V(`TO1FQA
M9W,@,S(@#2]&;VYT0D)O>"!;("TV,#0@+3(P-R`Q,S,X(#$P,S0@72`-+T9O
M;G1.86UE("]486AO;6$@#2])=&%L:6-!;F=L92`P(`TO4W1E;58@,"`-/CX@
M#65N9&]B:@TS,2`P(&]B:@T\/"`-+U1Y<&4@+T9O;G0@#2]3=6)T>7!E("]4
M<G5E5'EP92`-+T9I<G-T0VAA<B`R-#8@#2],87-T0VAA<B`R-#8@#2]7:61T
M:',@6R`U-#,@72`-+T5N8V]D:6YG("]7:6Y!;G-I16YC;V1I;F<@#2]"87-E
M1F]N="`O5&%H;VUA(`TO1F]N=$1E<V-R:7!T;W(@,S`@,"!2(`T^/B`-96YD
M;V)J#3,R(#`@;V)J#3P\(`TO5'EP92`O17AT1U-T871E(`TO4T$@9F%L<V4@
M#2]332`P+C`R(`TO5%(@+TED96YT:71Y(`T^/B`-96YD;V)J#3$@,"!O8FH-
M/#P@#2]4>7!E("]086=E(`TO4&%R96YT(#$Y(#`@4B`-+U)E<V]U<F-E<R`R
M(#`@4B`-+T-O;G1E;G1S(#,@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#<Y
M,B!=(`TO0W)O<$)O>"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@
M#65N9&]B:@TR(#`@;V)J#3P\(`TO4')O8U-E="!;("]01$8@+U1E>'0@72`-
M+T9O;G0@/#P@+U14,B`R-2`P(%(@+U14-"`R-R`P(%(@+U14."`Q,"`P(%(@
M+U14,3`@,3$@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S$@,S(@,"!2(#X^
M(`TO0V]L;W)3<&%C92`\/"`O0W,U(#(X(#`@4B`^/B`-/CX@#65N9&]B:@TS
M(#`@;V)J#3P\("],96YG=&@@,S`U-2`O1FEL=&5R("]&;&%T941E8V]D92`^
M/B`-<W1R96%M#0I(B9172Y/;N!&^SZ_`96O!U$@6J!>5V]B3S>Y6UKN540ZI
M=0X0"8U@DX3"AV3GA^>TAWS=#5+SM"LU52,21#_Q]=>-M]NK-]OM0AFUW5\9
M,YTMU`Q_\K29J;69T=.VNGKSKEVJO.7/,]7F5V_^>F?4?7N%#3,#^?QJ,CR>
MKW[7-\ERNM%E,IE/USH/];7Z*3$9ENK$3(W.I\JW;;*99KKG!5>H!,8VNCNX
M^+0/9;*>IH.2<&:5GM=$RWUB4JW>\[I+8'^M95.;3(Q6?W>ELZ0KE06G0LT2
MMR*1NXI\,GKG&F76U]%N.INET^1?VY^O3"KI2-5BE4T7F5JM$6-&^9!@YQ0W
MG@P]<=CE$*N!,S6L3N<(EK7!O51AP2S5]E84S)91`3^1@K?):KK4_Z5@EKK-
M#VJU86'(I>8BS2+IF'5Z).G?IK].U5O.4$@H[L_)A'*L5JEH6</7ISXL1A\6
MHF4UGQOUXQ^UJY&8!#(+9'HS7>EK=7?VW7^2R0HOKBEM7;!:8"@3#$W2!0%F
MDD[G:?332);&A)&%'T*C/%0:754.AV%T(:^VDU?5R&\I/Y;R.<<I4E;<8#,5
MFS,V=XG'C/&8!X?R?:M^"9_]GN(QA"G(Z/#9YKY6[V]OY(2>I";=#*KHB57E
MN3M2_&O=46H)=X290M;47A8#J=_H1OV`L]CH6^"`P'D#2)Y\,J&0W%D@-EV2
M^VDV&C6C41.-_O@'B3"<Z,<!^YOA91?7FGLZ'+*^UC@B/ASY5,B/FJA;(#Z9
M$.`KRJ<A82/2#'\"/K8-Z8VTD,ZF)D,5C/D=_#.S(2G(IIE354?LIWBN"<(;
M*O0/^OT_[_[R9ZHN??..MV[TWQ+*TX<DH;W\Z6!;M?>E$TA-Q.P3J*[&HUV)
M:<#QH(@R_C&]FR+;2P`SA$(!F>JVZ3GO*T;O`E8FY$%1^=JW76,['VHX)T*W
M-_`%T%AI9<$HR-("B9ZCA,ZO*3H>2Y\/6M[?BLP-#F=%<5$0VS]%O^>CW[$`
M]B@`<CL<#]W!EI7/5=_B=:^J\)F-S<%T`,92[\MQA<&*$OCNH5P;RIZ<F`+?
M"1W_<_E'RZS$M\H^=C$=78Q<<@R=JSNU#WW3'2:4FY3CS[2K'<%]H1N<7J8E
M!?NR#TWX=^_K4(;:28YLW?F=#QW<A+L=AYR'ZDC83(F?OB2&^6GG2N].KE5G
M7Y9X>^S;LV.WJK(?D4);G$@5GTWN%`(C"UTX^IP\A&]\A*7J&F>[BN(A9!RC
M"/F/8SYAG4)`]L.@C.7ZTH*GZKT`P^6TJYTJYA.D\!L)K,-9D?T5FE*JY<EW
M7OP=<@G,KH@?,I"#;#D>):WA%#?*,C,6L!?V_)4"Y77U7J2EQX!)ED^+9N23
M2[T2'\(\&%7."02H6B?4Z#X!&W`BVM]H6ZH!KCWU4>IL#-7N`!@537^/C$N&
MU6Z0R3O7^$@+"`#N2U6_X-^S_@/O/O8ULGU"NEH^L1'O5M4NU+8+35]=J['\
M2]O!H(K="CP'64GTT+O4L?&A\6#M-,4K`P^K@P1RN=`G'UD9AWI)W>1A[MK.
M)@MA?^I(/>#P*_O&J^0@/\!+_H6KLCTT"=%>S]VBDOKCC3N;/U0H8K(YZBI5
MD"U]R=E'"3_8Q/B<RP"TI&%#M!&>40[1C?,NVJ];<)7LEX40'=IY>8]N'+Y1
M@#AP*O(JU-WA0S*4!%%XV_6%QS0W\-A*>"B+/+30PS+SD!O>P#6M/SF*D#9_
M25)F6J[H)M:?BU7/D,U+T'ANR\>./L-2UWA;MM>D!?*'OK*U.N*T>(1I*IN'
M3[YV1%#B>#L05X&".+FX#R70Q7@6$@\H`CQW'Y<&-$4=+]7B[_J7%YC]168^
M^'M>/U`+I=*AG"S%"!!#A+\K'=!_\!@0;5F&<ZM\1U6X<ZH(+0W3'`7H#MJB
M_".E&.Q>+<AG0RG.-@='\CDL(]\#\F!,U%XC?&L)IKWXNM;@3>+^"1I4$W9^
M6"U1A:'H\Z[%43:?.&X,=!T<[D*!4S$T17&@2SV5(5AM#Q>JY;'H,O>:2+65
M39;Z$V9%S8DXT5/#PPU#";.S5K2VIQH!%%$4*1<,RF6)8F$!14IPI6#*7=(A
M88II.\7*B4RR!]J(1\SP=A3+0?2J`XT"&2MI>*4B5?*Q9_TEE_V2JTV[<9\G
MD9?`PX>17<@HD[`941L2I*I=<&%GC!>\!+K-9#KN(,I8,3FLAMVU:@^$',>+
M]4&VU+)'%HN$5"A9"OQR$GWRO6&#EK(*GI4U9>_M(S-(8>'%-?D?/XC6GK66
MW80_=2'^RA;1[T2_:(U?U/U@FQ8K61398V@]'^FK`,]&@,=$[J1?V>M8-RHO
M;0LHU7F)@J[OU5UGCP>>63*!)\XPY.#ER9IF!?0!;E-WZ(+'#A\8V9G.\[X=
MZE0TBT3H>;*B(OG&H.C:SE>6"B2;?4=-UW&1C&S`#+7D+A`?ARF%[?V4I*DT
MEY1WP<VR#:]PPE.BB1Y3+N.S6!`AZ^ED?VM=7P3T`<L9>!2-&=G8+"YY3B9S
MOCUZ>;`\@XG^QK5QM8W;0"+RH.)OB,>?]XT,W`T/W&[8)U<1[N\9?B:RJ2=*
MQ&PJ>S"A1F6UP_'`\_,`:O*E'#6Q80I,&M"]V+:#FL%)Y:HA*#%WGV2"?][&
M37M81.&+LA<3L=2/^YD9J=A$*F8I/C'<'#7-7+*`.-J>N@&NN3SBS"4%Q'"P
MATEDR#UC9LWS`ZGPLM:+PDK>&,RXJBVP%$V5\H6\G'.]S86IR43AX[M]C;Q>
MX&S<$XGS:B;$`5_057CI+P%,WD;6IHWRGUF9J)/VYD3Q(R7OA'9)HKZ(0<DU
M]82#98ZF_ZJ^[+R0],/5OI,U^HJ>]>.U:ICB^Q+S.UH$VT.S+GW7E=P[PE?Z
MZ;.AI`Z8%$C19AB/`),XIG(BS@=7TQ!>TB05;S7\0:I_'%\Q!*`+RY?V&*>5
M'!./E/)ES/75,30=JBD.3V`(7[@F7MVB\S-V?/&50:!V-$D2N[R#=W'"%D*@
M'.SW?&;H\7M/`\HP`RXER/7E+KOD88>MOMEN,V74=G\%5V%]QIAARV04&=E^
MI$T+V32C!,^^<KLYXGK:(3*,<G$@X3L(QA3?MKW#<-!\@;]F2#6=^II+?Z/+
M\EJ.$:[,-T\@;"X0-O$:"I"04#A'5$"IS&&?^!HKWW/^SWW+<-_<,.*,S/<;
MNLK9AUN$RY])\HV/][>]R/,TL]&#%;P,^F44>2@SHH<V<<6,>T6^3:@%$!.N
M.!T2V>./=-58L"#;BNY1NWD0P\-);75)V6J8U-@X(!F$*U'+X_^>N;R1,8+N
M=C0/=__OS?9Z:'VH`$/T2S><?$K-C^KH'.(=M2F+[P&$.5BA9$H$2HJ(Z0UC
MVFANMVM.&:%3QS+,+<_"N'2I/%1'6_-]Q<C(BI3>\+2XU@/Z<E%/OLDP<(A6
M+,.NQ=SNZM<)Y-GUJW`%)FX9FSFHP'=07#]S'%+1MS2KF_5``.B7-&Q4(5ZV
M&B?C^_\*KW;>A&$@O/=76.J22*4BH4`9*]1.#%7+UBD*AEHA,;*3\/?[W2/A
ML51(Q#B.<]R=O\=\:DC3#(L8/R"I`A!SITLM)%6>P)CY$V;AGKJ]\!?8I`-?
MW\J7?`Q409YXA)2^)5@0V_7"MDM&MFO).3!Y<49SSCLD(OD)Z5G0]JD&OS,G
M[6SOAF=3%@I/J$#3ZLXES[6H)UJ2?!(WYVV,RS'&Y25&,3*]BX2'6EV<`K$K
MG`JHMI;;'.>;:!>:-MHB,KG#PE#*7/0!H'IE(67;`7*%V<@G\+F\.BB+?,0[
M2#XTTX+4B#0^\)XZ`K0[`F/R:/!17%3PG``ZL8B@Z9YRLX%RUP4GQ*S)SX6&
MA.V'#^<B["8;[RL5NJU-,U8"64:ZBJ2DXG0VE7?A`,]>[X'Z)]G^PG(DC@C`
M0CT'>T2"K-3':1DF.2HTNT/6"TK(1GL-*H480US``W0$@HL<'/VJN2UE#`61
MH#2*%X)X,"VU7`O^FYIROO$97"^W=#/S+=>2OP%"24"E9"Z:#<8')LI_>OW+
M(N[:O)4MO2Y;K>;/\*X6&>"XJ8?)4O3^V&L'FZKQYX8;NVMD'%RLHI#0^_;A
M#[4!!H4*96YD<W1R96%M#65N9&]B:@TT(#`@;V)J#3P\(`TO5'EP92`O4&%G
M92`-+U!A<F5N="`Q.2`P(%(@#2]297-O=7)C97,@-2`P(%(@#2]#;VYT96YT
M<R`V(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@
M6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH--2`P(&]B
M:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#0@
M,C<@,"!2("]45#$P(#$Q(#`@4B`O5%0Q,B`Q,B`P(%(@/CX@#2]%>'1'4W1A
M=&4@/#P@+T=3,2`S,B`P(%(@/CX@#2]#;VQO<E-P86-E(#P\("]#<S4@,C@@
M,"!2(#X^(`T^/B`-96YD;V)J#38@,"!O8FH-/#P@+TQE;F=T:"`Q-3`X("]&
M:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)A%=)<]LV%+[K5^!(
M=DR&E$0MN:5QDK8SF>DTNG22'B@2DA"#!$L`HO7O^Q:(6ARGX[&)]:T?OO?\
MZV;R9K/),Y&+S6Z23T4&/_#)LY589NMT*C;-Y,U[6XC*TEXF;#5Y\^E++O9V
MDF1IEF4SL:DFY]$P^1KYMI*]*U7KE+2B;&MAW$'V8E=6SO16#`=5'413GD15
M>BN%\;THXR3/TEE4Q;.TB)POM>BE]=K9!]')?F?ZI@2QPO3Q/YL_)IE(\C0O
MQ.:1-2_1AN0\1"/**IZ#I(.2]#W27QDG!7P:7FN=%<Z(+<_`(,>C7I5:GWBQ
M5KM=6#U?$KO>-.!6.+'SSH<]$;ZCW7SQ;#SOQ6!F'IT=V?SR6A3+"FP_@L4+
MLAB-E<]=#W$"S\$3C).U$H+;"]5T6L%P>Z)@@L*A[.M$&_.DVKVP#EPC$:G8
M'*25MZJGH^HIJ[Z<!X]V6E9.0`+%4<G!"K,C'>!1N2?KYF2=*&D+S]5PF\?*
MB@[2B&*T+._UYJ/>'/5&@W('S'I'"DV(K(`@H"6(HQ*FVY*<;D&A]4WGE&EY
MT_KM]W"S5_:)%N/-]XN^8M17_`"HJ?BD0!-Z`)CT+0&RB*Y./(B3\<(>C->U
M:(T3G2XK/%I[*3@Q,TK,+-**T<KBQJW@/MFPND!VQ>:<TP825A'F#@"SB,8$
MTJR)40Z.VCB#8YC2CX3U1>1`#V0#GY@[E$XT:G]P@O?PH='@@M=%P.N"\8IQ
M.Z-]$0&F6KZI6:JO<6,9/9R=^!IMO<.,L"B,AU:-"G;6(.X!G0]*C=9FB)=@
ML6)Y[?XM^7DYTQEKU59IY4Z\P$Z89]*K=II&X`HYSL:=A8E!Z7AUL9;,V=[A
M;3[F?QZ>6-?UYLCO!H'[,4[6(.,QSD'!.WQ8U@-3\3%@)%"B0:JHI2Y/LD;_
M""7S"$G,5:8AW`?<XE94:=6JJM1CZLD&@KM#G@%0C>+A*HCHI%,.D"CJWN]Q
M4\-]1OG9S,=W\*P4F`<IN[H=P'[!>G(-=@[D;`SDC`)94"!G',AEU#X(GAO:
M:SJ,2$&(FT5H%R":Z,]PVF8`%+03'ION>:&L3_0-X.=Q4_9/-`J26!M&^*R.
M]#3=1=,QG/\Y5;%R0DHO@3(I0*A-.D`PS3@=X-@!:%VV9]*RL`]5":D+#K9R
M@)B:VE?N?W@9B,]C)?,]ODPD'E8'LP=`QI$)F_E9FXYI%#1HN8<L5<!>3%=[
M$TK>4?8MGKIAA]DE?T%O+_=>$Q#H.HA3EN>IB`%I?X,XU!DH*B;90%00EOJ*
MBDD+UOPIU_QIGA8YE'6LI!=L"L3256>0I=,5'_IA'J+`[X(H'(,.I"A[H*VV
MAKB@L`04+==W9?LE!U(FJ2$(G(:=P*N4!3T$KV[#;G/FR;&&+Z)K5@O4&6KX
M@,J&<)4_3#$=40ROW'!K*CX\\X*\.NA^6M?`*4,QD<\.T=;+?[WJ@74@1@0!
MJ.8](U5"T,!?2Q"%9@@P1CV4+@<&#9[JO0X0ND#"WEKPHM(!M!NO]Q"=D>R^
MR%$\ROJ`+W`9/<,K@2<BWINF4<#'!AAA".ET9:B)3Q+X]>>UW&RUVC-:P?O.
MP[32)^$[;@YZL/VH`##01H6V`2:O]RT/UX4\'Y7E(<!#G,PAC,C&&$U(%A9A
M[#G#T/`.MC.\H/D#_0(/D`!8B%"\TO*5W8T`:.3"A7`*_`-GPB'/A]S-[-S!
M\"+V`NF:F2^(Z"O?V+`-74.<+-$PBT?,Q9-@G;H1(U/*PG2>3@L!^XOQ9=WS
M1_01V\266E%'6:U,ZX#&WH:7/N>'#LH7L\LK?05.C\;O8R1L\3GT-F7U6YRL
M<.`<Q.1;]$Z#`JZ!O\?Y%#MG['RQ$V<0<:-DX3\"\9<,*/X6DS]P?#J]H@IR
M8)5ER1Q^5\5Z382R3O/EO:4OGM[G$ANS)43N%.=KC/RCARI`!L+&-/S+L<1$
M_DDH?6'-C_04%ZI<Y<ND*/)DE16K.];$'!5WE$<61L,PI"5&"+JL%(H^7ORP
MF?PW`#+KT$8*96YD<W1R96%M#65N9&]B:@TW(#`@;V)J#3P\(`TO5'EP92`O
M4&%G92`-+U!A<F5N="`Q.2`P(%(@#2]297-O=7)C97,@."`P(%(@#2]#;VYT
M96YT<R`Y(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!"
M;W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH-."`P
M(&]B:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]4
M5#(@,C4@,"!2("]45#0@,C<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S$@
M,S(@,"!2(#X^(`TO0V]L;W)3<&%C92`\/"`O0W,U(#(X(#`@4B`^/B`-/CX@
M#65N9&]B:@TY(#`@;V)J#3P\("],96YG=&@@.#0U("]&:6QT97(@+T9L871E
M1&5C;V1E(#X^(`US=')E86T-"DB)O%1-<]LX#+WK5^!(=B):I*BOW))-VNG.
M-+,3:T_;/2@R8WO&M5M)F6WZZXL/TJU[Z'''!XL@`+Z'!^"VSU9][\!"_YQU
MIJNAP!]_N*8TOH6ZJ4WIH/^4K?Z8*QAG]BA@'K/5N[6%[9SEA2D*ARG&K(#^
MO^P?M7ZO<UN82KU[N,$O;SK5:V><^OLQ'N_7^M_^3WK<R^.Y;8UWMH&\,HUO
MH+_+.&W#:8TMVD9R_Z7SQGCUHEO3J&G6""\>!LQM\73DTZ(1OX+E!,N.#0&F
M\$4\]U.(OI]TAUXAA>2MJ97DA-.S1@Z40LPIRSJ,,3ABV"_[$&/N\:947]D^
M[GY!E9?XMY4LNC"M`KQRQJH;;;T:V;3\>-9VI;_Z&;R$[IF7O"<<I^&XP.5C
M$<Y&$!Z$P"L?TJ/C()?B*H`VZ?*"\GYFK0K(K;%572=M/$O.ZELKXDSA\VE:
MM"=R\G<B-E;!4X!9-XR?S%LQ'^4O<'-LX!3/($Z20<(PP4XN!W8^4!LXA<6R
M]-@3]14R='3W@P7%Q["0K"\73V_0BOT8IH2.TVX3L,T57&:9PDN\B_RHR'R.
MB%XCA>$EN;$YQI\FH?8M;$R:@#A^KC155WC`-JF*<Y%M*P.`7TYJ?',83\<K
M>*\KU/Z('8"M9GZ9)M&J=!6GD;B/ZA&E1@I;9-H2TPXG=.8T"_806Y>/FE/E
MMC,.!48POFK:WTA^QSTHHDA):+:*ELYR%\9`;W4X;"A/IYY2R<&V5P!.*H.S
MKO.JK1KLQMM72M%X3+'ZJ0?D&SX,L<6DE*EGHKQK7>,LT>N[)*+X;<+$U!*S
MRV8NZS,S*CXQ>]"$=N!5Y@4\DM$6D5QC1IRO!*64OFD02X=C`VLL:H4HR'4G
M-@91GD'T;T33)&[4MN?UB&VX',(U`"X&1V.^G+`T:D*)N+@E-5DG<T+@:+G@
MA+P=QN52/&]JZZOS+CUW4E1N6$0J`G;'*EE'/&D5H$B>)&*-G&[/^M"^O-6T
MI96H1.MC16U4JQ6L%\GRC*1Q'>%>51"]!TUBB.,!2XM<?B.(]4F/U&@/VM("
MQ32(L73<:*SXM>::`9;=5JC8(N?PK)T5$*X@%#5'<\BL;<,PQ%.,_X,R]WWV
M78`!`&9@JHX*96YD<W1R96%M#65N9&]B:@TQ,"`P(&]B:@T\/"`-+U1Y<&4@
M+T9O;G0@#2]3=6)T>7!E("]4<G5E5'EP92`-+T9I<G-T0VAA<B`S,B`-+TQA
M<W1#:&%R(#$Q.2`-+U=I9'1H<R!;(#(U,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`S,S,@,C4P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(`TP
M(#`@,"`P(#`@-C8W(#`@,"`V-C<@,"`P(#`@,"`P(#8Q,2`P(#`@,"`P(#`@
M,"`U-38@,"`P(#`@,"`P(#`@#3`@,"`P(#`@,"`P(#`@-3`P(#`@-#0T(#4P
M,"`T-#0@,"`U,#`@,"`R-S@@,"`U,#`@,C<X(#<W."`U-38@-3`P(`TP(#`@
M,S@Y(#,X.2`R-S@@-34V(#`@-C8W(%T@#2]%;F-O9&EN9R`O5VEN06YS:45N
M8V]D:6YG(`TO0F%S949O;G0@+U1I;65S3F5W4F]M86XL0F]L9$ET86QI8R`-
M+T9O;G1$97-C<FEP=&]R(#$S(#`@4B`-/CX@#65N9&]B:@TQ,2`P(&]B:@T\
M/"`-+U1Y<&4@+T9O;G0@#2]3=6)T>7!E("]4<G5E5'EP92`-+T9I<G-T0VAA
M<B`S,B`-+TQA<W1#:&%R(#$R,2`-+U=I9'1H<R!;(#(U,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,C4P(#,S,R`R-3`@,"`P(#4P,"`P(#`@,"`U,#`@,"`P
M(#`@-3`P(`TS,S,@,"`P(#`@,"`P(#`@-C$Q(#`@-C8W(#<R,B`V,3$@-C$Q
M(#<R,B`P(#`@,"`P(#4U-B`P(#`@,"`V,3$@#3`@-C$Q(#4P,"`U-38@,"`P
M(#`@,"`U-38@,"`P(#`@,"`P(#`@,"`U,#`@-3`P(#0T-"`U,#`@-#0T(#(W
M."`--3`P(#4P,"`R-S@@,C<X(#0T-"`R-S@@-S(R(#4P,"`U,#`@-3`P(#4P
M,"`S.#D@,S@Y(#(W."`U,#`@-#0T(`TV-C<@-#0T(#0T-"!=(`TO16YC;V1I
M;F<@+U=I;D%N<VE%;F-O9&EN9R`-+T)A<V5&;VYT("]4:6UE<TYE=U)O;6%N
M+$ET86QI8R`-+T9O;G1$97-C<FEP=&]R(#$T(#`@4B`-/CX@#65N9&]B:@TQ
M,B`P(&]B:@T\/"`-+U1Y<&4@+T9O;G0@#2]3=6)T>7!E("]4<G5E5'EP92`-
M+T9I<G-T0VAA<B`S,B`-+TQA<W1#:&%R(#,R(`TO5VED=&AS(%L@,C<X(%T@
M#2]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG(`TO0F%S949O;G0@+T%R:6%L
M+$ET86QI8R`-+T9O;G1$97-C<FEP=&]R(#$U(#`@4B`-/CX@#65N9&]B:@TQ
M,R`P(&]B:@T\/"`-+U1Y<&4@+T9O;G1$97-C<FEP=&]R(`TO07-C96YT(#@Y
M,2`-+T-A<$AE:6=H="`P(`TO1&5S8V5N="`M,C$V(`TO1FQA9W,@.3@@#2]&
M;VYT0D)O>"!;("TQ.#0@+3,P-R`Q,C`V(#$P,S(@72`-+T9O;G1.86UE("]4
M:6UE<TYE=U)O;6%N+$)O;&1)=&%L:6,@#2])=&%L:6-!;F=L92`M,34@#2]3
M=&5M5B`Q,S,@#3X^(`UE;F1O8FH-,30@,"!O8FH-/#P@#2]4>7!E("]&;VYT
M1&5S8W)I<'1O<B`-+T%S8V5N="`X.3$@#2]#87!(96EG:'0@,"`-+T1E<V-E
M;G0@+3(Q-B`-+T9L86=S(#DX(`TO1F]N=$)";W@@6R`M,3@Y("TS,#<@,3$R
M,"`Q,#(S(%T@#2]&;VYT3F%M92`O5&EM97-.97=2;VUA;BQ)=&%L:6,@#2])
M=&%L:6-!;F=L92`M,34@#2]3=&5M5B`P(`T^/B`-96YD;V)J#3$U(#`@;V)J
M#3P\(`TO5'EP92`O1F]N=$1E<V-R:7!T;W(@#2]!<V-E;G0@.3`U(`TO0V%P
M2&5I9VAT(#`@#2]$97-C96YT("TR,3$@#2]&;&%G<R`Y-B`-+T9O;G1"0F]X
M(%L@+3(V,B`M,S(U(#$P.#(@,3`R-2!=(`TO1F]N=$YA;64@+T%R:6%L+$ET
M86QI8R`-+TET86QI8T%N9VQE("TQ-2`-+U-T96U6(#`@#3X^(`UE;F1O8FH-
M,38@,"!O8FH-/#P@#2]#;W5N="`Q(`TO1FER<W0@,3<@,"!2(`TO3&%S="`Q
M-R`P(%(@#3X^(`UE;F1O8FH-,3<@,"!O8FH-/#P@#2]4:71L92`H1F]R(&EM
M;65D:6%T92!R96QE87-E*0TO1&5S="!;(#$@,"!2("]&:71"(%T@#2]087)E
M;G0@,38@,"!2(`T^/B`-96YD;V)J#3$X(#`@;V)J#3P\(`TO4')O9'5C97(@
M*$%C<F]B870@1&ES=&EL;&5R(#0N,#4@9F]R(%=I;F1O=W,I#2]+97EW;W)D
M<R`H1F]R;2`V+4L@+2T@075G=7-T(%)E<&]R="YD;V,I#2]-;V1$871E("A$
M.C(P,#(Q,C$X,#@T,S0V+3`V)S`P)RD-+T%U=&AO<B`H06QC;VX@3&%B;W)A
M=&]R:65S+"!);F,N*0TO0W)E871I;VY$871E("A$.C(P,#(Q,C$X,#@T,S0S
M*0TO5&ET;&4@*%-%0U52251)15,@04Y$($580TA!3D=%($-/34U)4U-)3TXI
M#2]#<F5A=&]R("A-:6-R;W-O9G0@5V]R9"`X+C`I#3X^(`UE;F1O8FH-,3D@
M,"!O8FH-/#P@#2]4>7!E("]086=E<R`-+TMI9',@6R`R,B`P(%(@,2`P(%(@
M-"`P(%(@-R`P(%(@72`-+T-O=6YT(#0@#3X^(`UE;F1O8FH->')E9@TP(#(P
M(`TP,#`P,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#4W,#<@,#`P,#`@;@T*,#`P
M,#`P-3@U."`P,#`P,"!N#0HP,#`P,#`V,#(Y(#`P,#`P(&X-"C`P,#`P,#DQ
M-3@@,#`P,#`@;@T*,#`P,#`P.3,P.2`P,#`P,"!N#0HP,#`P,#`Y-#8Y(#`P
M,#`P(&X-"C`P,#`P,3$P-3$@,#`P,#`@;@T*,#`P,#`Q,3(P,B`P,#`P,"!N
M#0HP,#`P,#$Q,S0X(#`P,#`P(&X-"C`P,#`P,3(R-C8@,#`P,#`@;@T*,#`P
M,#`Q,C8X,"`P,#`P,"!N#0HP,#`P,#$S,3,Y(#`P,#`P(&X-"C`P,#`P,3,S
M,3D@,#`P,#`@;@T*,#`P,#`Q,S4R,2`P,#`P,"!N#0HP,#`P,#$S-S$W(#`P
M,#`P(&X-"C`P,#`P,3,Y,#4@,#`P,#`@;@T*,#`P,#`Q,SDV."`P,#`P,"!N
M#0HP,#`P,#$T,#8R(#`P,#`P(&X-"C`P,#`P,30S-3(@,#`P,#`@;@T*=')A
M:6QE<@T\/`TO4VEZ92`R,`TO241;/#-D8S<P8C%E,C(V,S%F,3%A83@S8C4R
M-S$V-V,Y-S@S/CPS9&,W,&(Q93(R-C,Q9C$Q86$X,V(U,C<Q-C=C.3<X,SY=
8#3X^#7-T87)T>')E9@TQ-S,-)25%3T8-
`
end

</PDF>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
